| Business Summary | | Pharsight
Corporation
develops
and
markets
integrated
products
and
services
that
help
pharmaceutical
and
biotechnology
companies
improve
the
drug
development
process.
The
Company's
solution
combines
proprietary
computer-based
simulation,
statistical
and
data
analysis
tools
with
strategic
decision
making
and
the
sciences
of
pharmacology,
drug
and
disease
modeling,
human
genetics
and
biostatistics.
The
Company's
solution
is
designed
to
help
its
customers
use
a
more
rigorous
scientific
and
statistical
process
to
identify
earlier
those
drug
candidates
that
will
not
be
successful
and
to
enhance
the
likelihood
that
the
remaining
candidates
will
successfully
complete
clinical
trials. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Pharsight
Corporation
develops
and
markets
integrated
products
and
services
that
help
pharmaceutical
companies
improve
the
drug
development
process,
combining
computer
simulation,
statistical
and
data
analysis
tools
with
strategic
decision
making.
For
the
three
months
ended
6/30/01,
total
revenues
rose
11%
to
$2.7
million.
Net
loss
applicable
to
Common
rose
20%
to
$6.5
million.
Results
reflect
expanded
relationships
with
customers,
offset
by
personnel
increases. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Arthur Reidel, 49 Chairman,
Pres, CEO | $200K | $1.5M | Ronald Beaver, Ph.D., 35 Managing
Director, Decision Services | -- | -- | Robin Kehoe, 43 Sr.
VP-Fin., CFO | 144K | 1.0M | Michael Emley, 53 Sr.
VP, Sales and Professional Services | 197K | -- | Daniel Weiner, Ph.D., 50 Sr.
VP, Technology Deployment | 175K | -- | Dollar
amounts are as of 31-Mar-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|